Core Insights - Onconetix, Inc. has appointed David White as Chief Executive Officer and Sammy Dorf to its Board of Directors, reflecting a strategic move to enhance leadership as the company prepares for the acquisition of Realbotix LLC, a developer of AI-powered humanoid robots [1][2][3] Leadership Appointments - David White brings over 30 years of executive experience, having held CEO, CFO, and COO roles in various sectors including transportation and healthcare. He has served on multiple public company boards and holds a CPA designation [2][4] - Sammy Dorf is an entrepreneur and investor with a strong background in capital markets and corporate governance. He co-founded Verano Holdings Corp. and has held significant roles in public companies, contributing to their strategic transformations [3][4] Acquisition of Realbotix - The acquisition of Realbotix is seen as a transformative opportunity for Onconetix, positioning the company at the intersection of AI and humanoid robotics, which is a rapidly evolving sector [3][5] - The leadership team believes that the acquisition will create significant value for shareholders and is focused on executing the transaction successfully [5][6] Company Background - Onconetix, Inc. is a commercial-stage biotechnology company specializing in innovative oncology solutions, including Proclarix®, an in vitro diagnostic test for prostate cancer [6] - Realbotix LLC, the target of the acquisition, develops AI-powered humanoid robots designed for human interaction, with patented technologies enabling lifelike expressions and social engagement [7]

Core Insights - Onconetix is set to acquire Realbotix LLC, which has recently demonstrated its humanoid robot in a live pre-standard 6G trial conducted by Ericsson, marking a significant milestone for both companies [1][2][5]. Group 1: Acquisition Details - Onconetix has entered into a definitive share exchange agreement to acquire 100% of Realbotix LLC in an all-stock transaction [5]. - The acquisition is expected to close in the second half of 2026, pending shareholder and regulatory approvals [5]. Group 2: Technological Developments - Realbotix's humanoid robot was featured as a live robotics endpoint during Ericsson's 6G over-the-air trial, showcasing its capabilities in real-time video transmission and interaction [2][3]. - The demonstration highlighted the potential of next-generation wireless networks to support AI-driven technologies, emphasizing high-speed and low-latency connectivity [3]. Group 3: AI Integration - Realbotix's AI-agnostic architecture allows its humanoid robots to integrate with various AI systems and cloud platforms, enabling operation across diverse ecosystems without reliance on a single AI provider [4].

Core Viewpoint - Onconetix, Inc. has announced a 1-for-5 reverse stock split of its outstanding shares, effective March 25, 2026, to comply with Nasdaq's minimum bid price requirement of $1.00 per share [1][2]. Group 1: Reverse Stock Split Details - The reverse stock split will convert every 5 shares of common stock into 1 share, reducing the number of outstanding shares from approximately 3.6 million to about 0.7 million [3][4]. - The reverse stock split will not affect the number of authorized shares or the ownership percentage of stockholders, except for fractional shares, which will be compensated in cash [3][4]. - The common stock will continue to trade under the symbol "ONCO" on The Nasdaq Capital Market with a new CUSIP number [2]. Group 2: Company Overview - Onconetix, Inc. is a commercial-stage biotechnology company focused on men's health and oncology, owning Proclarix®, an in vitro diagnostic test for prostate cancer [5]. - Proclarix® has been approved for sale in the European Union and is anticipated to be marketed in the U.S. as a lab-developed test through a license agreement with Labcorp [5].

Core Viewpoint - Onconetix, Inc. is acquiring Realbotix LLC in an all-stock transaction, aiming to enhance shareholder value through the integration of Realbotix's advanced humanoid robotics technology [1][4]. Company Overview - Onconetix, Inc. is a biotechnology company focused on oncology solutions, including the Proclarix® diagnostic test for prostate cancer [8]. - Realbotix LLC specializes in AI-powered humanoid robotics, designed for customer-facing roles across various industries such as healthcare, education, hospitality, and entertainment [2][9]. Transaction Details - The share exchange agreement allows Onconetix to acquire 100% of Realbotix's equity interests, with Realbotix Parent expected to hold between 75% and 90% of the combined company's shares post-transaction [4][5]. - The transaction has been unanimously approved by the boards of both companies and is subject to customary closing conditions, including shareholder approval and regulatory clearances [5]. Technological Advancements - Realbotix is recognized for its patented technologies that enable lifelike expressions and social interactions, allowing its robots to operate autonomously without human teleoperation [3]. - The robots are equipped with advanced vision systems capable of interpreting emotional visual cues and situations, enhancing their functionality in public venues [3]. Strategic Importance - The merger is viewed as a strategic move to unlock significant value for shareholders and to position the combined entity for future growth in the humanoid robotics market [4]. - Andrew J. Oakley, Chairman of Onconetix, expressed excitement about the potential to change the company's strategic direction through this acquisition [3].

Core Insights - Onconetix, Inc. has completed a private placement of Series D Convertible Preferred Stock and Warrants, raising approximately $12.9 million [1][2] - The financing transaction involved $9.3 million in cash and the remainder used to offset debts [1][3] - The proceeds will be used to settle debts, cover costs related to a terminated business combination, and for working capital [3] Financing Details - The private placement includes shares convertible into 4,362,827 shares of Common Stock and Warrants to purchase the same number of shares [1] - The initial exercise price for the Warrants is set at $3.6896 per share, with anti-dilution adjustments applicable [1] - The Company will seek stockholder approval for the issuance of shares related to the Series D Preferred Stock and Warrants [2] Debt Settlement - Approximately $6.3 million of the financing proceeds were allocated to settle a debt with Veru, Inc., while $2.5 million of debt was converted into Series D Preferred Stock and Warrants [3] - The total debt owed to Veru, Inc. was approximately $8.8 million [3] Company Overview - Onconetix, Inc. is focused on innovative solutions for men's health and oncology, including the Proclarix® diagnostic test for prostate cancer [4] - The Company has acquired Proteomedix, enhancing its product offerings in the oncology space [4]

Core Viewpoint - Onconetix, Inc. and Ocuvex Therapeutics, Inc. have mutually terminated their merger agreement, deciding to pursue independent paths for the benefit of their stakeholders [1][2]. Company Summaries Onconetix, Inc. - Onconetix is a commercial-stage biotechnology company focused on innovative solutions for men's health and oncology [4]. - The company owns Proclarix®, an in vitro diagnostic test for prostate cancer, which is approved for sale in the European Union under the IVDR [4]. Ocuvex Therapeutics, Inc. - Ocuvex is dedicated to advancing ophthalmic science and improving patient outcomes through innovative research and product development [5]. - The company has received its New Jersey state pharmaceutical license and plans to launch Omlonti in the coming weeks [3].

Core Viewpoint - Onconetix, Inc. has announced a licensing agreement with Immunovia AB for the production of antibodies related to pancreatic cancer diagnostics, which is expected to enhance the early detection of pancreatic cancer through the PancreaSure test [1][2]. Group 1: Licensing Agreement Details - Proteomedix AG, a subsidiary of Onconetix, will provide Immunovia with master cells necessary for producing antibodies for three of the five biomarkers in the PancreaSure test [2]. - The agreement includes a license for key intellectual property related to the manufacturing of reagents for measuring these biomarkers, allowing Immunovia to purchase reagents directly from Proteomedix [2]. - Immunovia will pay a total of $700,000 to Proteomedix in 2025 and 2026, along with a 3% royalty on net sales of PancreaSure and other products using the licensed intellectual property from 2026 to 2032 [3]. Group 2: Company Focus and Products - Onconetix is focused on innovative solutions for men's health and oncology, with a particular emphasis on the early detection of prostate cancer through its Proclarix® test [4][5]. - Proclarix® is CE-certified and indicated for prostate cancer diagnosis in patients with specific clinical conditions, demonstrating reliability in detecting clinically significant prostate cancer [6].

Core Viewpoint - Onconetix, Inc. has entered into a definitive merger agreement with Ocuvex Therapeutics, Inc., aiming to enhance its portfolio with ophthalmic therapeutic candidates and create significant value for shareholders [1][2]. Company Overview Onconetix - Onconetix is a commercial stage biotechnology company focused on innovative solutions for men's health and oncology, including the Proclarix® diagnostic test for prostate cancer [6]. Ocuvex - Ocuvex is a privately held biopharmaceutical company specializing in ophthalmic therapeutic candidates, with its lead asset, Omlonti® (omidenepag isopropyl ophthalmic solution) 0.002%, approved by the FDA for ocular hypertension and open-angle glaucoma [8]. Transaction Details - The merger agreement has been approved by the boards of directors of both companies, with Onconetix acquiring all equity interests of Ocuvex [3][4]. - Ocuvex equity holders will receive newly-issued shares of Onconetix common stock equal to 90% of the combined company’s equity interests post-transaction, while Onconetix shareholders will retain 10% [4]. - The board of directors of the combined company will consist of seven directors, with five from Ocuvex and two from Onconetix [5]. Anticipated Timeline - The completion of the proposed transaction is expected in the fourth quarter of 2025, subject to customary conditions including regulatory and stockholder approvals [5].

Core Viewpoint - Onconetix, Inc. and Ocuvex Therapeutics, Inc. have signed a Non-Binding Letter of Intent for a potential business combination, which aims to enhance Onconetix's portfolio beyond oncology and increase shareholder value [1][2]. Company Overview Onconetix, Inc. - Onconetix is a commercial stage biotechnology company focused on men's health and oncology, with products like Proclarix®, an in vitro diagnostic test for prostate cancer, and ENTADFI, an FDA-approved treatment for benign prostatic hyperplasia [4]. Ocuvex Therapeutics, Inc. - Ocuvex is a privately held biopharmaceutical company specializing in ophthalmic therapeutic candidates, formed from the merger of Ocuvex Inc. and Visiox Pharmaceuticals, Inc. in August 2024. Its lead asset, Omlonti®, is an FDA-approved treatment for ocular hypertension and open-angle glaucoma [6]. Transaction Details - The proposed transaction will involve Onconetix acquiring all equity interests of Ocuvex in exchange for newly issued shares of Onconetix, with pre-closing Ocuvex equity holders expected to own approximately 90% of Onconetix post-transaction [2][3]. - The Letter of Intent indicates mutual interest but is subject to due diligence, financing, and regulatory approvals, with no assurance that a definitive agreement will be executed [3].